Outcome metrics of intravenous golimumab for hidradenitis suppurativa

Summary: Abstract Body: Infliximab (IFX), a chimeric monoclonal antibody targeting tumor necrosis factor (TNF)-α, is a weight-based therapy for hidradenitis suppurativa (HS). However, IFX is contraindicated after IFX-associated-anaphylaxis (IAAx) or when neutralized by IFX-associated antibodies (IAAb). Intravenous (IV) golimumab (Gol), a fully humanized IFX congener, has been proposed for refractory HS. Objective: Examine outcome metrics in a cohort treated with IV-Gol for HS. We surveyed 17 HS patients treated with IV-Gol for 3-months after IAAx or IAAb. Demographic data, HS severity (HS-physician global assessment(HSPGA), numerical rating scale for pain (NRS-Pain) and inflammatory markers (C-reactive protein(CRP), erythrocyte sedimentation rate(ESR), interleukine-6(IL-6) were collected pre- and post-IV-Gol. Study participants were surveyed with standardized questions, grading drainage, mood, sleep quality, mobility, quality of life(QoL), willingness to receive IV-Gol again if discontinued, and overall preference for IV-Gol versus IFX. Mean cohort age was 40 years; 15 female (88%); racial/ethnic distribution: 9 Black, 2 White, 1 Spanish/Hispanic/Latino, 5 Other. There were mean declines (≥3-months) in HSPGA (-1.294) and NRS-Pain (-1.647). All inflammatory markers trended downwards. Neither allergy nor antibodies occurred. Survey participants reported improved or similar lesion status (15[88%]), pain (13[76%]), drainage (13[76%]), mood (16[94%]), mobility (15[88%]), sleep (16[94%]), and QoL (15[88%]) compared to IFX. All reported ‘satisfied’ or ‘very satisfied’ with IV-Gol. All were willing to undergo IV-Gol again; 14(82%) preferred IV-Gol over IFX or had no preference. Outcome metrics among HS patients receiving IV-Gol offer a highly promising alternative weight-based (TNF)-α inhibitor in the setting of IAAx and IAAb. Hansen Tai¹, Aarthi Parvathaneni¹, Khyla Hill¹, Zahidul Islam², Eden Axler³, Steven Cohen¹ 1. Dermatology, Weill Cornell Medicine, New York, NY, United States. 2. New York Medical College School of Medicine, Valhalla, NY, United States. 3. Albert Einstein College of Medicine, New York, NY, United States. Clinical Research: Epidemiology and Observational Research